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Introduction
There are many similarities between the lung aging process and chronic obstructive pulmonary disease (COPD), and many of the characteristics of aging are present in COPD, suggesting that accelerated aging may be a pathogenic mechanism in COPD (MacNee 2016). In fact, many of the changes that occur in the lungs with normal aging, such as declining lung function, deterioration of respiratory muscle strength, increased air trapping, loss of lung elastic recoil, and increased distal airspaces, are also present in COPD (MacNee 2016 , van Wetering et al. 2008 . Moreover, in the elderly population, the presence of cardiovascular, osteoarticular, and neurological abnormalities can lead to subclinical COPD symptoms and underdiagnosis of the disease. Therefore, routine evaluation using pulmonary function tests (PFTs) in elderly patients with risk factors for COPD are essential (Incalzi et al. 2014) .
The loss of muscle strength and/or endurance is an important systemic effect of aging and drops sharply for aging associated with COPD (Evans et al. 2015 , Maltais et al. 2014 . These impairments have countless consequences in COPD patients, including low exercise tolerance, decreased quality of life, greater need for healthcare, and increased morbidity and mortality.
Dysfunction of the lower limb muscles was even shown to better predict mortality than lung function measurements in COPD patients (Swallow et al. 2007) . In recent years, isokinetic dynamometry has been used in clinical practice and is currently the standard method for assessing muscle function (Homem et al. 2017) . However, to our knowledge, the contributions of the isokinetic tests have not been previously evaluated in the elderly populations with COPD.
In COPD, exercise intolerance is multifactorial. Exercise limitations reflect the reduced ventilatory capacity, abnormal gas exchange, and skeletal muscle dysfunction in these patients, especially for the muscles involved in walking. As a result, the exercise capacity and maximum work rate are reduced (Borghi-Silva et al. 2009) . In this context, ventilatory limitation has been identified as one of the contributors to exercise intolerance, since those with COPD cease exercise because they cannot increase ventilation in response to increasing metabolic demands (O'Donnell, 2001) . Several factors determine ventilatory limitation during cardiopulmonary exercise testing (CPET), including abnormal ventilatory mechanics, increased ventilatory demand, and changes in the neuroregulatory 4 control of breathing (O'Donnell 2001) . In addition to ventilatory limitation, peripheral muscle dysfunction syndrome also seems to play a fundamental role in exercise intolerance in patients with COPD (Malaguti et al. 2011 , Van't Hul et al. 2004 . Some investigators have suggested that exercise intolerance is partly due to skeletal muscle dysfunction, and in 40-45% of COPD patients, muscle discomfort of the lower limbs is the main symptom that limits physical activity (Borghi-Silva et al. 2009 ). Despite these studies, this issue has not been addressed specifically in the elderly who suffer from COPD.
In elderly persons with COPD, exercise intolerance has a negative impact on the healthrelated quality of life (HRQL). Several factors may potentially impair performance during exercise in elderly patients with COPD, and understanding the mechanisms involved in functional capacity reduction may help identify new ways of approaching therapy and physical reconditioning for COPD.
Thus, the objective of the present study was to evaluate what characteristics related to lung function, peripheral muscle strength and endurance can predict the performance of elderly patients with COPD during cardiopulmonary exercise testing (CPET).
Material and Methods

Participants
Between April 2015 and March 2017, a cross-sectional study was conducted that evaluated 97 consecutive patients with COPD who were recruited at Newton Bethlem Hospital, Rio de Janeiro, Brazil. Only patients aged ≥60 years were included. The diagnosis of COPD was established by spirometry showing a post-bronchodilator forced expiratory volume in one second/forced vital capacity (FEV 1 /FVC) ratio of less than 0.7 and a smoking history of more than 10 pack-years (GOLD 2018). Patients with history or radiographic evidence of tuberculosis, bronchiectasis or other pulmonary disorders, those taking oral prednisolone or undergoing supplemental oxygen therapy, those with respiratory exacerbations in the past four weeks, those undergoing pulmonary rehabilitation in the past 12 months, and those with any conditions that prevented CPET were excluded. The cases were classified as stages 1-4 (classification of airflow limitation severity) and A-D (assessment of symptoms and risk of exacerbations) according to the Global Initiative for Chronic
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Obstructive Lung Disease (GOLD) (2018) . The project was approved by the Research Ethics Committee of the Augusto Motta University Center under number CAAE-52885116.6.0000.5235 and was in compliance with the provisions of the Declaration of Helsinki. All participants signed a consent form.
Resting lung function
Spirometry and the measurement of diffusion capacity of the lung for carbon monoxide (DLco) were carried out using a Collins Plus Pulmonary Function Testing System (Warren E. Collins, Inc., Braintree, MA, USA). DLco was measured using the single breath-hold method measurements with a rapidly responding gas analyzer, and the prediction values of DLco were adjusted according to hemoglobin levels (Graham et al. 2017) . The FEV 1 value was used to assess the degree of airway obstruction. Both PFTs followed the guidelines of the American Thoracic Society (Miller et al. 2005) .
Reference values for the Brazilian population were considered , Pereira et al. 2007 ).
In addition, all participants performed a nitrogen (N 2 ) single-breath washout (SBW) test using HDpft 3000 equipment (nSpire Health, Inc., Longmont, CO, USA), following standard recommendations (Robinson et al., 2013) . Two parameters derived from the SBW test were analyzed, and both were interpreted as percentages of the predicted values (Buist and Ross 1973) : the phase III slope of SBW (SIII N2 ), which is defined as the change in the N 2 concentration from 25-75% of the expired volume and considered a marker of ventilation distribution, and the closing volume/vital capacity (CV/VC) ratio, which is defined as the portion of the VC that is exhaled after the initiation of airway closure and is considered a marker of small airway disease (Lopes and Mafort 2014).
Knee isokinetic dynamometry
The quadriceps and hamstring muscles of the dominant lower limb were evaluated using a Biodex System 4 PRO dynamometer (Biodex Medical System, Shirley, NY, USA) at the Admiral Adalberto Nunes Physical Education Center (Brazilian Navy), Rio de Janeiro, Brazil. Briefly, the participants were seated in the equipment, and the trunk, pelvis, and thigh were stabilized using belts.
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The rotational axis of the dynamometer was aligned with the lateral epicondyle of the femur, while the range of motion for performing the test was set at 90°. Before the test, the patient underwent familiarization training with three submaximal repetitions (Homem et al. 2017 , Lopes et al. 2016 .
After this step, strength analysis was performed through an angular velocity of 75°/s with two sets of five repetitions. Subsequently, the participant performed the endurance evaluation through an angular velocity of 240°/s with two sets of 15 repetitions (Justo et al. 2017) . A rest period of two minutes was given between the tests. The highest value of the different repetitions of each of the following variables was analyzed: peak torque (PT), which is the maximum force produced at a given point of the range of motion (determined in extension) and was evaluated at 75°/s (PT75°/s) and 240°/s (PT240°/s), and agonist/antagonist ratio (AG/ANT), which is the PT of the hamstrings divided by PT of the quadriceps and was evaluated at 75°/s (AG/ANT75°/s) and at 240°/s (AG/ANT240°/s) (Walchan et al. 2016) .
Cardiopulmonary exercise testing
CPET was performed on a treadmill (Inbramed, ATL, Porto Alegre, Brazil) as subject's respiratory gases were collected using a metabolic analyzer (MedGraphics VO2000, Medical Graphics, Inc., St. Paul, MN, USA) that was operated according to standard procedures (American Thoracic Society and American College of Chest Physicians 2003) . A ramp protocol with individualized incline and load was used. The capacity of each individual was adapted so that the duration of exercise intensity was between 8 and 12 minutes, and the subsequent peak oxygen uptake (VO 2 peak) values were calculated. For interpretations of the VO 2 peak, the reference values for the Brazilian population were considered .
Sample size
Considering the association between the VO 2 peak and pulmonary or muscle function variables as the main outcome of this study, a minimal sample size of 36 participants was necessary to observe a minimal correlation of 0.41 (weak or higher) at a 5% significance level and 80% study power.
Statistical analysis
Variables were described as the mean ± SD or number (percentage) as appropriate. Bivariate associations were examined using the two-tailed Pearson's r correlation coefficient between VO 2 peak (% predicted values) and clinical (age, sex ['male' = 1 and 'female' = 0], body mass index (BMI), pulmonary (FEV 1 , DLco, SIII N2 , and CV/VC), peripheral muscle strength (PT75°/s and AG/ANT75°/s) and endurance (PT240°/s and AG/ANT240°/s) variables. Independent linear regression models were generated to explore the role of clinical, pulmonary, and peripheral muscle function variables as predictors of VO 2 peak. Due to the proportion of the minimum number of variables per participant for developing prediction models (10:1) (Babyak 2004) , our model included up to four independent variables simultaneously. We grouped variables to determine to what extent the independent predictors related to the same domain can predict the dependent variable. The models of muscle strength and endurance that were examined included age, gender, or BMI as covariates, provided they were identified as significantly correlated to VO 2 peak. Because lung function variables were included as percentages of the predicted values (already considering general confounders), this model did include other covariates. The adjusted R 2 and respective p-values as calculated from analysis of variance (ANOVA) tables were used to evaluate the fit of each model; regression coefficients and the respective 95% confidence intervals (95% CIs) are also reported alongside the pvalues. Multicollinearity was assessed using the variance inflation factor (VIF). Differences were considered statistically significant at p<0.05 with a 95% confidence interval. Analyses were conducted using SPSS 22 (SPSS, Chicago, IL, USA).
Results
Subject characteristics
Of the 97 participants eligible for evaluation, 40 completed the study (see Figure 1 ). The mean age was 70.2±7.46 years, and the smoking load was 45.2±19.8 pack-years. The clinical data, lung and muscle function, and CPET results are summarized in Table 1 .
Correlation analysis
The Explaining the VO 2 peak using clinical, pulmonary function, and peripheral muscle function variables
The average VO 2 peak was significantly predicted by all models (p=0.008 or lower). Tables 2   and 3 show the raw and adjusted models after controlling for possible confounders. Figures 2 and 3 show the regression plot for each tested model accordingly. The clinical model yielded an even higher explained variance (44.2%), with age as the sole independent predictor negatively associated with VO2 peak (p<0.001) identified in this analysis.
The model including peripheral muscle strength variables exhibited the lowest explained variance (19%), whereas neither the PT nor AG/ANT at 75°/s were independent predictors of VO 2 peak (p=0.074 or higher). After controlling for age, both PT and AG/ANT at 75°/s were not independent predictors of VO 2 peak (p=0.125 or higher). Conversely, the model including peripheral muscle endurance variables showed a higher explained variance (42.8%), and both PT and AG/ANT at 240°/s were independent predictors positively associated with VO 2 peak (p=0.006 or lower). After adjustment for age, both PT and AG/ANT at 240°/s remained as independent predictors of VO 2 peak (p=0.041 or lower). Finally, the pulmonary function model showed the highest explained variance (50.9%) in which SIII N2 , DLco, and FEV 1 (p=0.010 or lower) but not CV/VC (p=0.170) were found to be independent predictors of VO 2 peak. In this last model, SIII N2 was negatively associated with VO 2 peak, whereas DLco and FEV 1 were both positively associated. Multicollinearity was not identified in any model, as assessed by low VIF values (VIF=1.499 or lower). After adjustment for age, however, only SIII N2 and DLco remained as independent predictors of VO 2 peak (p=0.013 or lower).
Discussion
This study contributes the following new findings to our knowledge of systemic manifestations in elderly patients with COPD. Deterioration of lung function is the main contributor to poor performance during exercise in the elderly population with COPD. Thus, the greater the heterogeneity in the ventilation distribution and the decrease in pulmonary diffusion are, the lower the VO 2 peak. In elderly people with COPD, muscle endurance (i.e., loss of the ability to sustain a specific task over time) but not muscle strength contributes strongly to exercise performance. In addition, older age was the only demographic variable that negatively impacted performance during the CPET.
The CPET provides an overview of the systems involved in transporting oxygen from ambient air to mitochondria and shows the performance of these systems during exercise. Among the four models we constructed before controlling for age as independent confounder (see Table 2 ), the model including clinical variables presented an explained variance of almost 45% for VO 2 peak, with age being the only independent predictor of VO 2 peak. This finding is in line with those from a study by Betik and Hepple (2008) , which demonstrated that VO 2 peak decreases by an average of 10% per decade after the age of 30 due to the decreases in maximal heart rate, stroke volume, blood flow to skeletal muscle and skeletal muscle aerobic potential. Since the main feature of COPD is its progressive course with steadily increasing multisystem involvement (GOLD 2018), an even greater decline in VO 2 peak is expected as aging progresses. In elderly patients with COPD, a reduced ability to perform physical exercise is a complicating factor and increases the mortality associated with et al. 2014) . Since age was the sole independent predictor negatively associated with peak VO 2 (p <0.001), it is worth noting that the other models were then age-controlled as a confounding factor (see Table 4 ).
In COPD, increased ventilatory demand during exercise worsens air trapping and causes dynamic hyperinflation (DH) above the already increased resting volumes; DH, in turn, compromises the ability of the inspiratory muscles to generate adequate intrathoracic pressures (O'Donnell 2001) .
In the present study, the pulmonary function model for elderly patients with COPD was the one that presented the highest explained variance for VO 2 peak, surpassing 65% after controlling for age as an independent confounder. In this model, the pulmonary function variable that presented the greatest explanatory power was the elevation of SIII N2 , which denotes heterogeneity in the ventilation distribution due to inefficient ventilation and greater ventilatory demand during exercise. Importantly, the main mechanism that generates alteration in ventilation comes from convection-dependent inhomogeneity in the conducting airway zone (i.e., airways proximal to terminal bronchioles), which contributes to an increased SIII N2 in SBW (Crawford et al. 1985 , Robinson et al. 2013 . In view of the difficulty of performing CPET in elderly patients with COPD because of the contraindications inherent to the test, we believe that SBW may contribute as a predictor of poor performance during Nevertheless, for our pulmonary function model proposed for elderly patients with COPD, the drop in pulmonary diffusion was also a predictor of reduced VO 2 peak during exercise. Similar to our findings, Franssen et al. (2004) demonstrated that DLco, along with age and fat-free mass, explained 56% of the VO 2 peak variance in COPD patients. Another study also found that DLco and quadriceps strength were independently associated with VO 2 peak in these patients (van Wetering et al. 2008) . In addition to varying with age, sex and height, DLco values also depend upon a number of physiological factors including hemoglobin levels, lung volume, carboxyhemoglobin, oxygen inspired tension, and exercise (Graham et al. 2017) . Thus, our study provides further evidence that DLco may be a useful marker of exercise intolerance in elderly patients with COPD, especially in those with predominant emphysema and consequently reduced membrane surface area available for gas exchange (Neder et al. 2017) . Interestingly, we also observed that FEV 1 -the marker of the degree of airway obstruction most commonly used in clinical practice-did not enter our pulmonary function model after controlling for age as an independent confounder. Interestingly, the potential relationship between ventilatory inefficiency and exertional dyspnea in patients with symptomatic COPD and preserved FEV 1 was already clearly established in a previous study (Franssen et al. 2004) . This result reinforces the importance of a more detailed evaluation of lung function, in addition to FEV 1 , in this population of patients.
Muscle dysfunction in COPD shows a regional distribution, with relative preservation of muscle function of the trunk and upper limbs and deterioration of lower limb muscle function (Malaguti et al. 2011 , Van't Hul et al. 2004 . Thus, specific muscle groups of interest should be tested, since muscle weakness does not affect all muscles in a similar way, with variations depending on the anatomical region studied (Pleguezuelos et al. 2016 , Robles et al. 2011 . Using knee isokinetic dynamometry, we were able to demonstrate the negative impact of lower limb muscle dysfunction on VO 2 peak in elderly patients with COPD. Potential factors contributing to aging-related functional impairment in COPD patients include reduced motor neuron activity and changes in muscle morphology and energy metabolism leading to apoptosis, muscle atrophy, oxidative stress, reduced muscle capillarity, and intramuscular fat accumulation (Franssen et al. 2004 , Robles et al. 2011 ). In addition, there are several adjuvant factors responsible for peripheral muscle dysfunction in these patients, including deconditioning/disuse, local inflammation, tissue hypoxia, hypercapnia, nutritional depletion, corticosteroid use, and hormonal changes, which promote structural and functional changes in contractile tissue (Evans et al. 2015 , Janaudis-Ferreira et al. 2006 , Maltais et al. 2014 , Pleguezuelos et al. 2016 , Robles et al. 2011 . The relationship between lower limb muscle dysfunction and clinical outcomes in COPD suggests that clinical evaluation of muscle dysfunction in these patients may identify those at increased risk of exercise intolerance and premature death (Maltais et al. 2014) .
Interestingly, the aging process may impact peripheral muscle function differently in individuals with COPD. In fact, our models that included the peripheral muscle function variables reached an explained variance of VO 2 peak of 19% for muscle strength and 42.8% for muscle endurance. However, only the muscular endurance variables presented as independent predictors after controlling for age as a confounding factor (p=0.041 or lower). These differences can be justified at least in part by the significant deviation in the proportion of muscle fibers from type I to type II, the reduction in capillarity, and the altered metabolic enzyme levels (Borghi-Silva et al. 2009 , van den Borst et al. 2013 . In line with our findings, Malaguti et al. (2011) observed that in patients with COPD, muscle endurance and aerobic capacity are more greatly affected than muscle strength, even in patients with preserved muscle mass. However, there is no consensus about the main mechanisms involved in the decreasing muscle endurance in these patients. While one study showed that the impairment of quadriceps muscle endurance was associated with physical inactivity and the degree of pulmonary obstruction (Serres et al. 1998) , another study demonstrated that quadriceps endurance was impaired independently of the level of physical activity (Coronell et al. 2004 ). More recently, Malaguti et al. (2011) reported that muscle atrophy seems to be the main determinant in the reduction of muscle strength among patients with COPD, whereas endurance reduction seems to be more related to the imbalance between oxygen supply and consumption due to low capillarity, bioenergetic abnormalities, and intrinsic alterations in the muscle contractility of the lower limbs.
Finally, in our muscle endurance model, both the reduction of the PT240°/s and the decrease in the AG/ANT240°/s ratio contributed to the decrease in VO 2 peak. The AG/ANT ratio is one of the parameters that has aroused great interest in isokinetics since this value describes the muscle balance in the knee joint. A change in the relationship between the PT of the hamstrings and the quadriceps indicates that there are excessive muscle imbalances, which predisposes the knee joint to injury (Walchan et al. 2016) . Thus, lower limb training in elderly patients with COPD with consequent improvement in the AG/ANT ratio can provide several benefits, including greater exercise tolerance and better HRQL, since upper limb training has not shown the same benefits (Evans et al. 2015) .
The strength of this study is that it is the first to evaluate the contribution of lung and muscle functions in exercise performance in elderly patients with COPD using the gold standard methods.
However, like any study, ours also has limitations. First, we acknowledge that including GOLD stages as an independent variable to the pulmonary function model would be interesting from a clinical point of view. However, as related to lung function, our study focused on what variables predict CPET performance in patients with COPD. In this way, the inclusion of GOLD stages would not further understanding of the pathophysiologic mechanisms that may impair exercise tolerance in these subjects. Second, measurements of static lung volumes and peripheral muscle strength could possibly have contributed to increase the explained variance of the pulmonary function model for VO 2 peak.
Third, the inclusion of the six-minute walk test could have allowed the creation of models for distance traveled, since this test is much more commonly used in clinical practice due to its simplicity. Despite these limitations, our results may be important for establishing rehabilitation strategies for elderly patients with COPD, since the findings suggest that both lung function and lower limb muscle function play a prominent role in the functional capacity of these subjects. These results become even more significant when considering that only 20% of pulmonary rehabilitation programs use a detailed assessment of pulmonary and peripheral muscle function in COPD patients (Spruit et al. 2014 ).
In conclusion, the present study shows that ventilation distribution and pulmonary diffusion, but not the degree of airway obstruction, independently predict CPET performance in elderly patients with COPD. Aging has a differential impact on the lower limb muscle function in elderly patients with COPD, whereas peripheral muscle endurance but not strength also predicts CPET performance in these subjects. In addition, older age is the main demographic variable that reduces functional capacity during exercise in the elderly population with COPD.
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22 Table 3 . Independent linear models of peak oxygen uptake (% predicted) using muscle function and pulmonary function after controlling for age as independent confounder (n=40). Regression plots of the peak oxygen uptake (VO 2 peak) models (measured vs. predicted) after controlling for age as an independent confounder. The adjusted R 2 for the models of VO 2 peak were as follows: muscle strength, R 2 =0.510; muscle endurance, R 2 =0.574; and pulmonary function, R 2 =0.656.
Model
